Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

First RNA Antagonist Medicine to Be Tested in Patients Reduces Severity of Adult Leukaemia

Copenhagen, 6th June 2007 - Santaris Pharma, the Danish biopharmaceutical company, announced today that SPC2996, the Company's new RNA Antagonist of Bcl-2, has shown early evidence of efficacy in an initial Phase I/II clinical study in Chronic Lymphocytic Leukaemia (CLL). The results of the study were reported this week at the 2007 Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois.

The clinical trial was conducted in patients with advanced CLL, the most common form of adult leukaemia, and involved 12 centres in France, Britain, Denmark, and the USA. Conclusions from the study were as follows.

*A reduction in the number of cancerous B-lymphocytes (white blood cells) and a beneficial effect on lymph nodes and overall tumour response was observed in patients given 6 repeated doses of drug at 4mg/kg/infusion over a two week period, with the effects on lymphocytes being seen within 24 hours of the first dose.

*A relationship between dose of SPC2996 and activity was observed in the study, with higher doses giving improved effects on lymphocyte counts, lymph nodes, time to progression and overall tumour response.

*SPC2996 treatment was associated with statistically significant reduction in mean Bcl-2 levels in white blood cells from CLL patients, supporting the intended mechanism of action of the drug.

Commenting on the results, Prof Bertrand Coiffier, from the Hospices Civils de Lyon, University of Lyon, France, the international coordinating investigator for the study, said:

"These results are early stage but promising. All patients came into this study with clinically progressing CLL. Despite this, patients receiving the drug at an effective level had rapid and sustained falls in circulating cancerous lymphocytes. There also appeared to be e
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... 22, 2015  Amgen (NASDAQ: AMGN ) today announced that ... results on Tuesday, Jan. 27, 2015, after the close of the ... call with the investment community at 2 p.m. PT. Participating in ... chairman and chief executive officer, and other members of Amgen,s senior ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... Suggests that Adding Singulair to Advair Offers no Additional ... Improvement in ... TORONTO, May 18 /PRNewswire-FirstCall/,-- Patients with both asthma and ... when treated with Advair,Diskus(R) (fluticasone propionate and salmeterol inhalation ...
... ASCO Annual Meeting Will Further Demonstrate, the ... CAMBRIDGE, Mass., May 16 Millennium Pharmaceuticals,The Takeda ... studies are scheduled to be featured at the 2008 ... Illinois, May 30 -,June 3, 2008. The data will ...
Cached Medicine Technology:Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 2Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
(Date:1/22/2015)... (PRWEB) January 23, 2015 AngelWeddingDress, the ... of 2015 maternity wedding dresses. View website ... are looking for maternity wedding dresses online for a ... gowns with high quality for them. Its maternity wedding ...
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 EBSCO Information ... (AMA) are expanding their relationship in an effort to further ... the world. While EBSCO has long made AMA journals available ... sales agent for The JAMA Network. , Long ...
(Date:1/22/2015)... Richmond, VA (PRWEB) January 22, 2015 ... the power at the Science Museum of Virginia. Wicked ... 24. , Wicked Plants unearths 75 poisonous, carnivorous and ... traverse through each room to uncover the biochemical, physical ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... too low when benefits are so high , , THURSDAY, ... at the levels health-care providers and policymakers would like, two ... , Representatives of the U.S. Centers for Disease Control and ... of the Department of Health and Human Services, are spending ...
... , , , TAMPA, ... Health Management Solutions for health plans, is named among the 5,000 fastest ... , , (Logo: http://www.newsco m ... The leading business magazine recognizes the nation,s fastest-growing, privately held ...
... , WASHINGTON, Aug. 13 The following ... Improving access to affordable, comprehensive health care has been ... of the America,s Affordable Health Choices Act (H.R. 3200) will make ... includes: , , , ...
... ... has done a summary analysis of the health care plan currently under consideration in Congress. ... the plan are simply not true (There is no coverage for illegal aliens, and the ... there is still serious concern on the financial side. , ...
... , NEW YORK, Aug. 13 His mission is to ... consequences. Chef Lindsey Williams, grandson of Sylvia Woods, owner of Sylvia,s ... ," a collection of traditional soul food dishes made with healthier cooking ... named after iconic Harlem figures this weekend during Harlem Week. ...
... , - Healthcare Reform Proposals in Congress Set ... by $130.2 Million over Ten Years - , , ... Mexico Congressional Delegation to Stop and Revise Further Cuts to Seniors, ... N.M., Aug. 13 Area nursing home caregivers, residents and family ...
Cached Medicine News:Health News:It's Time for More Moms to Breast-Feed, U.S. Officials Say 2Health News:It's Time for More Moms to Breast-Feed, U.S. Officials Say 3Health News:Health Integrated Named to the 2009 Inc. 5000 2Health News:Analysis of the Proposed Health Care Legislation Finds Financial Aspects May be Difficult to Forecast 2Health News:Queen of Soul Food's Grandson on Mission to Get Harlem Kids to Eat Healthier 2Health News:Queen of Soul Food's Grandson on Mission to Get Harlem Kids to Eat Healthier 3Health News:State, National Nursing Home Caregivers: Medicare Funding Cut to Long Term Care Will Jeopardize Vital Staffing Positions and Compromise Care for New Mexico's Seniors 2Health News:State, National Nursing Home Caregivers: Medicare Funding Cut to Long Term Care Will Jeopardize Vital Staffing Positions and Compromise Care for New Mexico's Seniors 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: